Showing 5191-5200 of 21466 results for "".
- Low-Dose Rivaroxaban in Advanced CKD: TRACK Trial Resultshttps://reachmd.com/news/low-dose-rivaroxaban-in-advanced-ckd-track-trial-results/2487367/Key Takeaways Low-dose rivaroxaban was not associated with a lower primary cardiovascular composite in adults with advanced CKD, including those receiving dialysis. Major bleeding was more frequent with rivaroxaban than placebo, rising from 6.0% to 8.8
- Digital Stewardship Cut Antibiotic Use for ARIs in Rural Facilitieshttps://reachmd.com/news/digital-stewardship-cut-antibiotic-use-for-aris-in-rural-facilities/2487361/Key Takeaways Antibiotic prescribing was substantially lower in intervention consultations, with adjusted analyses favoring the stewardship program. The intervention was a comprehensive, digitally enabled stewardship program, while control facilities c
- CAN 2409 Plus Radiotherapy Extends Disease-Free Survivalhttps://reachmd.com/news/can-2409-plus-radiotherapy-extends-disease-free-survival/2487363/Key Takeaways Disease-free survival favored CAN 2409 plus valacyclovir over placebo plus valacyclovir during the reported follow-up. Men were randomly assigned 2:1 to three intraprostatic CAN 2409 courses at 5 × 10^11 viral particles plus valacyclovir
- Study: Mineral Sunscreen Whitening Linked to Reduced Application and Protectionhttps://reachmd.com/news/study-links-mineral-sunscreen-whitening-to-reduced-application-and-protection/2487379/New research published in the Journal of Drugs in Dermatology indicates mineral sunscreens produced visible whitening across all skin tones, with a pronounced effect in darker skin tones. Investigators evaluated 5 mi
- Review Examines Glycation’s Expanding Role in Cutaneous Aginghttps://reachmd.com/news/review-examines-glycations-expanding-role-in-cutaneous-aging/2487357/A narrative review published in the Journal of Cosmetic Dermatology examines the growing evidence linking glycation and advanced glycation end products (AGEs) to skin aging, highlighting potential implications for both dermatology and aesthetic medicine. In the review, Diala Hayka
- Phase 3 Bepirovirsen Trial Shows HBsAg Loss In Chronic Hepatitis Bhttps://reachmd.com/news/bepirovirsen-hbsag-chronic-hepatitis-b/2487336/Key Takeaways Week-72 functional cure occurred more often with bepirovirsen than with placebo in both trials. Response rates were higher among participants with lower baseline HBsAg concentrations. Adverse events, including grade 3 or higher e
- Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Cancerhttps://reachmd.com/news/daraxonrasib-metastatic-pancreatic-cancer/2487354/Key Takeaways Daraxonrasib was associated with longer overall survival and progression-free survival than investigator's choice chemotherapy in the prespecified RAS G12 population. Benefit was also reported in the overall population, and 91.8% of enrol
- TDN Grading in Aneurysmal Subarachnoid Hemorrhagehttps://reachmd.com/news/tdn-aneurysmal-subarachnoid-hemorrhage/2487350/Key Takeaways Investigators retrospectively applied TDN to charted adverse events in 355 treated patients, and higher grades were associated with longer hospitalization and poorer recovery. Higher TDN grades were linked to lower Glasgow Outcome Scale s
- Brepocitinib Phase 3 Trial Findings in Dermatomyositishttps://reachmd.com/news/brepocitinib-dermatomyositis-trial/2487352/Key Takeaways Brepocitinib 30 mg was associated with a higher week-52 Total Improvement Score than placebo in adults with dermatomyositis. The 30-mg dose was also superior across all nine key secondary end points, with improvement observed by week 4.</
- Corsair Pharma Reports Phase 1 Results for TRX-248 in PAHhttps://reachmd.com/news/corsair-trx-248-pah/2487353/Key Takeaways After single-dose patch use, treprostinil plasma levels remained steady over 24 hours with limited peak-to-trough variation. Corsair reported acceptable safety and skin tolerability, and exposure increased proportionally across patch size